When does appetite suppression start with Mounjaro — and what shapes the timing?

What to expect in the first two to four weeks

The 2.5 mg starting dose exists primarily to let your digestive system adjust, not to deliver the full therapeutic effect. Think of it less as a treatment dose and more as a settling-in period. Many people do notice a shift in hunger during this phase (smaller appetite at mealtimes, less pull toward snacking in the evening) but it is often quieter than what comes later. The NHS medicines information for tirzepatide describes this gradual titration approach, and the clinical rationale is sound: pushing straight to a higher dose increases the likelihood of nausea and other GI side effects.

By weeks three to four, when the first dose increase typically happens (timing set by your prescriber), most people report a clearer reduction in appetite. The stomach empties more slowly, early fullness arrives sooner, and the background noise of food thoughts quietens. Keeping your pen in the fridge door and injecting on the same day each week can help build the routine that makes these early weeks easier to track.

If you reach week three with no noticeable change at all, that is worth raising with your prescriber rather than assuming the medicine is failing. There is a separate resource on why some people experience no appetite suppression on Mounjaro and what the clinical options are.

Why suppression deepens as the dose increases

The appetite effect is not a switch that flips once, it builds with the dose. Clinical trial evidence from SURMOUNT-1, published in the New England Journal of Medicine, showed the greatest weight loss at the highest doses (10 mg and 15 mg), which reflects a dose-dependent appetite response. Participants on 15 mg achieved around 20–21% average body-weight reduction over 72 weeks. Those results emerge because the dual GIP and GLP-1 receptor activation becomes progressively stronger, reinforcing satiety signals more robustly at each step.

Practically, this means the question of when appetite suppression starts has two honest answers: a mild version often arrives early, and the fuller version arrives once you reach a dose that is genuinely therapeutic for your biology. Titration is not a formality. It is the mechanism by which the medicine finds its effective level in your system. The tirzepatide appetite suppression page covers the receptor biology in more detail if you want to understand what is driving the change.

Your prescriber sets the titration schedule based on your response and tolerance, this is not something to adjust independently. What you eat during this period does influence how comfortable the process feels; the guidance on what to eat on Mounjaro is worth reading before your first injection.

When appetite suppression starts to wear off (and what that signals

A question our prescribers hear regularly: appetite came back) is that normal? The short answer is that fluctuations across a dose cycle are common. Mounjaro is injected once weekly, and some people notice hunger returning slightly in the day or two before their next dose. This is not the medicine failing; it reflects the natural pharmacokinetic curve of a weekly injection.

What is different is persistent return of appetite across the whole week, particularly if it was well-controlled before. That pattern can signal that you have reached the ceiling of a given dose and may benefit from the next titration step, something to discuss with your prescriber, with evidence of your current weight and response. The fuller picture on appetite suppression wearing off includes what to bring to that conversation. For context on how Mounjaro compares to other options in terms of appetite effect and weight outcomes, the Mounjaro cost and context page touches on the broader treatment landscape.

Mounjaro's appetite-suppression profile is one reason it is the only dual-agonist weight-loss medicine currently licensed in the UK. You can read more about the medicine overall on the Mounjaro treatment page, and the weight-loss treatment overview sets it alongside other licensed options. The NHS medicines page for tirzepatide is the clearest patient-level reference for what to expect day to day.

Making the decision: is this normal, or do you need support?

The honest frame for this page's question is that appetite suppression with Mounjaro is not one moment but a trajectory. Early weeks are often a preview. The fuller effect arrives with the dose. And when suppression plateaus or dips, that is information your prescriber needs, not a reason to stop.

If you are weighing whether the timeline sounds right for your situation, or you have not yet started treatment and are trying to understand what the first weeks will feel like, the guide on when food suppression starts on Mounjaro covers the practical week-by-week picture in more detail. NICE's recommendation for tirzepatide (TA1026) notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing treatment should be reviewed, which underlines why consistent clinical oversight matters throughout, not just at the start.

If you are considering starting treatment and want a prescriber to review your situation, speaking to our prescribers is the place to begin. Every consultation is reviewed by a GPhC-registered Independent Prescriber the same day, a real clinician, reading your answers.